UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 38

Sortiert nach

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Clinical cancer research, 2016-11, Vol.22 (22), p.5461-5471

2016

Link zum Volltext

Verfügbarkeit prüfen

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

The lancet oncology, 2013-11, Vol.14 (12), p.1233-1242

2013

Link zum Volltext

Verfügbarkeit prüfen

A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting

PloS one, 2015-04, Vol.10 (4), p.e0120877

2015

Link zum Volltext

Verfügbarkeit prüfen

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

Journal for immunotherapy of cancer, 2019-02, Vol.7 (1), p.49-49, Article 49

2019

Link zum Volltext

Verfügbarkeit prüfen

Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison

Supportive care in cancer, 2016-10, Vol.24 (10), p.4159-4166

2016

Link zum Volltext

Verfügbarkeit prüfen

Transarterial Yttrium-90 Radioembolization Treatment of Patients with Liver-Dominant Metastatic Renal Cell Carcinoma

Journal of vascular and interventional radiology, 2017-02, Vol.28 (2), p.254-259

2017

Link zum Volltext

Verfügbarkeit prüfen

Course and Moderators of Hot Flash Interference during Androgen Deprivation Therapy for Prostate Cancer: A Matched Comparison

The Journal of urology, 2015-09, Vol.194 (3), p.690-695

2015

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study

JAMA oncology, 2017-09, Vol.3 (9), p.e172411

2017

Link zum Volltext

Verfügbarkeit prüfen

A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma

European urology, 2021-08, Vol.80 (2), p.162-170

2021

Link zum Volltext

Verfügbarkeit prüfen

Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison

Journal of clinical oncology, 2015-06, Vol.33 (18), p.2021-2027

2015

Link zum Volltext

Verfügbarkeit prüfen

Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma

Targeted oncology, 2017-06, Vol.12 (3), p.333-340

2017

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer

Cancer, 2017-12, Vol.123 (23), p.4566-4573

2017

Link zum Volltext

Verfügbarkeit prüfen

Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma

Clinical cancer research, 2020-11, Vol.26 (21), p.5598-5608

2020

Link zum Volltext

Verfügbarkeit prüfen

Effect of androgen deprivation therapy on sexual function and bother in men with prostate cancer: A controlled comparison

Psycho-oncology (Chichester, England), 2018-01, Vol.27 (1), p.316-324

2018

Link zum Volltext

Verfügbarkeit prüfen

Targeted therapy of kidney cancer: keeping the art around the algorithms

Cancer control, 2013-07, Vol.20 (3), p.222-232

Fishman, Mayer N

2013

Link zum Volltext

Verfügbarkeit prüfen

Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison

Supportive care in cancer, 2016-05, Vol.24 (5), p.2201-2207

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264―272)/HLA-A0201 Complex, in Patients with Advanced Malignancies

Clinical cancer research, 2011-12, Vol.17 (24), p.7765-7775

2011

Link zum Volltext

Verfügbarkeit prüfen

Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma

Clinical genitourinary cancer, 2016-12, Vol.14 (6), p.499-503

2016

Link zum Volltext

Verfügbarkeit prüfen

Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy

World journal of urology, 2016-11, Vol.34 (11), p.1567-1573

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of the Taxane BMS-188797 in Combination with Carboplatin Administered Every 3 Weeks in Patients with Solid Malignancies

Clinical cancer research, 2006-01, Vol.12 (2), p.523-528

2006

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of a Novel Taxane BMS-188797 in Adult Patients with Solid Malignancies

Clinical cancer research, 2005-05, Vol.11 (9), p.3335-3341

2005

Link zum Volltext

Verfügbarkeit prüfen

Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer

Cancer control, 2013-01, Vol.20 (1), p.7-16

2013

Link zum Volltext

Verfügbarkeit prüfen

Cytoreductive nephrectomy vs medical therapy as initial treatment: a rational approach to the sequence question in metastatic renal cell carcinoma

Cancer control, 2010-10, Vol.17 (4), p.269-278

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 38

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(38)

Sprache

Englisch
(38)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(31)
Life Sciences & Biomedicine
(30)
Male
(27)
Oncology
(24)
Aged
(20)
Middle Aged
(19)
Female
(17)
Adult
(14)
Treatment Outcome
(12)
Carcinoma, Renal Cell - Drug Therapy
(11)
Kidney Neoplasms - Drug Therapy
(11)
Kidney Neoplasms - Pathology
(11)
Neoplasm Staging
(11)
Aged, 80 And Over
(9)
Renal Cell Carcinoma
(9)
Antineoplastic Agents - Therapeutic Use
(8)
Carcinoma, Renal Cell - Pathology
(8)
Kidney Cancer
(8)
Retrospective Studies
(7)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison

Transarterial Yttrium-90 Radioembolization Treatment of Patients with Liver-Dominant Metastatic Renal Cell Carcinoma

Course and Moderators of Hot Flash Interference during Androgen Deprivation Therapy for Prostate Cancer: A Matched Comparison

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study

A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma

Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison

Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma

Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer

Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)

Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma

Effect of androgen deprivation therapy on sexual function and bother in men with prostate cancer: A controlled comparison

Targeted therapy of kidney cancer: keeping the art around the algorithms

Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison

Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264―272)/HLA-A0201 Complex, in Patients with Advanced Malignancies

Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma

Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy

A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience

Phase I Study of the Taxane BMS-188797 in Combination with Carboplatin Administered Every 3 Weeks in Patients with Solid Malignancies

Phase I Study of a Novel Taxane BMS-188797 in Adult Patients with Solid Malignancies

Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer

Cytoreductive nephrectomy vs medical therapy as initial treatment: a rational approach to the sequence question in metastatic renal cell carcinoma

Aktive Filter

Suchergebnisse filtern